Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 839-848

  Gazitt, Yair ^a   Rothenberg, Mace L ^b   Hilsenbeck, Susan G ^b   Fey, Valerie ^a   Thomas, Charles ^b   Montegomrey, Willie ^a  

^a Univ of Texas Health Science Center ^*  (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bcl 2; Drug resistance; Myeloma

Indexed keywords

GEMCITABINE; PACLITAXEL; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031687587     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.839     Document Type: Article

References (63)

1. Barlogie B, Smith L and Alexanian R: Effective treatment of multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1356, 1984.
2. Barlogie B, Hall R, Zander A, Dicke K and Alexanian R: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67: 1298-1302, 1986.
3. Gregory W, Richards M and Malpas J: Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 336-341, 1992.
4. Blade J, San Miguel JE, Alcala A, Maldonado J, Sanz MA, Conde JG, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, Brito GG, Martin JH, Calvo, JF, Rubio D, Ortega F, Jimenez R, Colominas P, Faura MV, Font L, Tortosa J, Dimingo A, Fontanillas M, Rozman C and Estape J: Alternating combination VCMP/VBAP chemotherapy vs. melphalan/ prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 11: 1165-1171, 1993.
5. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Dreyfus F, Troussard X, Brechignian S, Mariette X and Bruet JC: High dose therapy and autologous blood stem cell transplantation in multiple myeloma. Blood 82: 2005-2010, 1993.
6. Tricot G, Jagannath S, Vesole DH, Crowley J and Barlogie B: Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 16: 7-11, 1995.
7. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R and Crowley J: High dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplantation. Blood 84: 950-956, 1994.
8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JE, Casassus P, Maisoneuve H, Facon T, Ifrah N, Payen C and Bataille R: A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97, 1996.
9. Gazitt Y and Reading CL: Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Leuk Lymphoma 23: 203-212, 1996.
10. Boccadoro M, Palumbo A, Argentino C, Dominietto A, Frieri R, Avisati G, Comotti B, Luta VM, Liberati M, Marmot F, Musto P, Tribalto M and Pileri A: Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Haematol 96: 333-337, 1997.
11. Bouffard DY, Momparler LF and Momparler RL: Comparison of antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs 2: 49-55, 1991.
12. Peters GS and Plunkett W: Gemcitabine - Status of preclinical studies and perspective for future clinical application of this novel nucleoside analog. Semin Oncol 22: 1-2, 1995.
13. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
14. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self potentiation. Cancer Res 52: 533-539, 1992.
15. Gandhi V, Leghr J, Chen F, Hertel LW and Plankett W: Excision of gemcytabine monophosphate from DNA. Cancer Res 56: 4453-4459, 1996.
16. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN and Plunkett W: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991.
17. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J and Harris A: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
18. Shepherd FA: Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 6 (Suppl. 6): 19-23, 1995.
19. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenbecrg ML, Modano MR, Cripps CM, Portenoy RK, Storniolo AM, Tarassoff P, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
20. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Stoniolo AM and von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU- refractory pancreas cancer. Ann Oncol 7: 347-353, 1996.
21. Le Chevalier T: Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol 23 (Suppl. 10): 36-42, 1996.
22. Moore MJ, Tannock IF, Ernst DS, Huan S and Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445, 1997.
23. Rowinsky EK, Cazenave LA and Donehower RC: Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990.
24. Rothenberg ML: Taxol, taxotere and other new taxenes. Curr Opin Invest Drugs 2: 1269-1277, 1993.
25. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
26. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz MS and Leherer PJ: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270, 1994.
27. Hortobagyi G and Holmes FA: Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 23 (Suppl. 1): 4-9, 1996.
28. Younes A, Ayoub J-P, Sarris A, Hagemeister F, North L, Pate O, MaLaughlin P, Rodriguez AM, Kurzrock R, Preti A, Bachier C, Smith T and Cabanillas F: Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report for a phase II trial. Br J Haematol 96: 328-332, 1997.
29. Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delsalle K and Alexanian R: Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol 5: 757-759, 1994.
30. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 53: 4701-4714, 1993.
31. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
32. Yang E and Korsmeyer SJ: Molecular thanatopsis: A discourse on bcl-2 family of proteins. Blood 88: 386-401, 1996.
33. Tsujimoto Y, Crossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1442, 1985.
34. Reed JC, Kitada S and Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's l lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: s61-s65, 1994.
35. Hermine O, Haioun C, Lepage E, D'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F and Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodskin's lymphoma. Blood 87: 265-272, 1996.
36. Robertson LE, Plunkett W, McConnell K, Keating MJ and McDonnell JT: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-459, 1996.
37. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y and Nilson K: Expression of bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79: 495-502, 1992.
38. Tian E and Gazitt Y: The role of P53, bel and bax in dexamethasone induced apoptosis in myeloma cell lines. Int J Oncol 8: 719-726, 1996.
39. Hu W-X and Gazitt Y: Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 9: 375-381, 1996.
40. Tian E, Hu W-X and Gazitt Y: Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: a study with inducible bcl-2 transfection constructs. Int J Oncol 9: 165-169, 1996.
41. Gazitt Y, Fey V, Thomas C and Alvarez R: Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13: 397-405, 1998.
42. Gazitt Y, Lavia MF and Erdos GW: Regulation of cell growth and apoptosis in synchronized AGF cells: involvement of oncogenes and cell cycle regulatory proteins. Int J Oncol 3: 489-496, 1993.
43. Gazitt Y and Erdos GW: Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 54: 950-956, 1994.
44. Greco WR, Bravo G and Parsons JC: The search for synergy: a critical review from a response surface perspective. [Review]. Pharmacol Rev 47: 331-385, 1995.
45. Laska EM, Meisner M and Siegel C: Simple designs and model-free tests for synergy. Biometrics 50: 834-841, 1994.
46. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G and Bhalla K: High levels of bcl-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994.
47. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C and Bhalla K: Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML cells. Leukemia 11:253-257, 1997.
48. Willingham M and Bhalla K: Transient mitotic phase localization of bcl-2 in human carcinoma cells and its possible role in prevention of apoptosis. J Histochem Cytochem 42: 441-450, 1994.
49. Haldar S, Chintapalli J and Croce M: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
50. Ibrado AM, Liu L and Bhalla K: Bclx overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis in human acute myeloid leukemia HL-60 cells. Cancer Res 57: 1109-1115, 1997.
51. Haldar S, Jena N and Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
52. Chen C-Y and Faller DV: Phosphorylation of bcl-2 protein and association with p21-ras in ras induced apoptosis. J Biol Chem 271: 2376-2379, 1996.
53. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, and Neckers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf signal pathway. Cancer Res 56: 1851-1854, 1996.
54. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L and Fojo T: Raf/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
55. Haldar S, Basu A and Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
56. Gruber J, Geisen F, Sgonc R, Agle A, Villunger A, Boeck G, Konwalinka G and Grcil R: 2′2′-difluorodeoxy cytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-cdA). Stem Cells 14: 351-362, 1996.
57. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L: Taxol induction of P21 and P53 requires c-raf-1. Cancer Res 55:4623-4626, 1995.
58. Tishler RB, Lamppu DM, Park S and Price BD: Microtubule-active drugs taxol, vinblastin and nocodazole increase the level of transcriptionally active p53. Cancer Res 56: 6021-6025, 1995.
59. Debernardis D, Graniela S, Tire E, DeFeudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M and Broggini M: p53 status does not affect sensitivity of human ovarian cancer cells to paclitaxel. Cancer Res 57: 870-874, 1997.
60. Huizing MT, Keung AFC and Rosing H: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135, 1993.
61. Teoh G, Urashima M, Ogata A, Chauhan D, Dccaprio JA, Treon SP, Schlossman RL and Anderson CK: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90: 1982-1992, 1997.
62. Guchelaar H-J, Richel DJ and van Knapen A: Clinical toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22: 15-31, 1996.
63. Rothenbcrg, ML, Sharma A, Weiss GR, Villanova-Callero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burns HA, Eckhardt SG, Stephens CD, Forral K, Nichol S and von Hoff DD: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol (In press).